
Results
8
Companies which are more than 50% undervalued based on analyst price target.
8 companies
Caliway Biopharmaceuticals
Market Cap: NT$161.1b
Engages in the development of drugs for aesthetic medicine and chronic inflammation.
6919
NT$103.50
7D
-1.4%
1Y
-19.8%
Bora Pharmaceuticals
Market Cap: NT$48.2b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$378.50
7D
-5.6%
1Y
-45.6%
Lotus Pharmaceutical
Market Cap: NT$46.4b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$176.50
7D
-7.3%
1Y
-20.5%
Oneness Biotech
Market Cap: NT$20.9b
Engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan.
4743
NT$43.65
7D
-8.7%
1Y
-31.7%
TaiMed Biologics
Market Cap: NT$15.8b
A biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases.
4147
NT$58.00
7D
-0.9%
1Y
-28.7%
Medigen Vaccine Biologics
Market Cap: NT$15.3b
A biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.
6547
NT$46.50
7D
-0.3%
1Y
7.9%
EirGenix
Market Cap: NT$13.9b
Operates as a contract development and manufacturing company in Taiwan and internationally.
6589
NT$45.95
7D
1.0%
1Y
-29.3%
Foresee Pharmaceuticals
Market Cap: NT$12.7b
Operates as biopharmaceutical company in the United States, China, and Europe.
6576
NT$80.70
7D
-1.8%
1Y
9.6%